Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT02608099
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 300 participants
- Registry
-
NCT02608099
-
- Other papers using this trial's data
- A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02608099. Randomized; no masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2017-04 (actual). Results posted on 2020-03-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
- Acronym
- AEIOU
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Interrupted apixaban
- Intervention (Drug)
- Uninterrupted apixaban
- Lead sponsor
- Baim Institute for Clinical Research
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct02608099- Content hash
7eae9e25902697923b36ffafab009163b0d49db0584bb8b64230682848e70f68